Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

  • STATUS
    Not Recruiting
  • End date
    Mar 31, 2023
  • participants needed
    42
  • sponsor
    Lawrence Fong
Updated on 10 October 2022
prostatectomy
cancer
prednisone
anticoagulants
endocrine therapy
serum bilirubin
erythropoietin
testosterone
metastasis
neutrophil count
hormone therapy
antiandrogen therapy
bone scan
antiandrogens
abiraterone
leuprolide
bone metastases
stereotactic body radiation therapy
adenocarcinoma
adenocarcinoma of prostate

Summary

This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in patients with newly diagnosed hormone-naive oligometastatic prostate cancer.

Description

This randomized phase II trial studies how well androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without toll-like receptor 9 (TLR9) agonist SD-101 in treating patients with prostate cancer and cancer in all oligometastatic sites that has spread to other places in the body. Androgen can cause the growth of tumor cells. Androgen deprivation therapy, such as leuprolide acetate, prednisone, and abiraterone acetate may lessen the amount of androgen made by the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Colony-stimulating factors, such as TLR9 agonist SD-101, may increase the production of blood cells. It is not yet known whether giving androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without TLR9 agonist SD-101 may work better in treating patients with prostate cancer and cancer in all oligometastatic sites.

PRIMARY OBJECTIVES

  • Cohort 1 (No longer recruiting)

--To assess the safety associated with giving RT and pembrolizumab with or without intratumoral SD-101.

  • Cohort 2
  • To continue to assess the safety associated with giving RT and pembrolizumab with or without intratumoral SD-101.
  • To assess if the rate of PSA < nadir + 2 ng/mL at 15 months in patients with non-castrate levels of testosterone is greater than the historical control in each study arm.

SECONDARY OBJECTIVES

  • To determine the rate of testosterone-PSA uncoupling in each study arm in cohort 2. Testosterone-PSA uncoupling is defined as PSA < 50% baseline and < 20ng/mL for at least 3 months after testosterone recovers to >150 ng/dL. In patients with metastatic hormone sensitive prostate cancer off hormonal therapy, >90% patient are expected to have PSA increase to > 50% baseline after 3 months of testosterone recovery.
  • To estimate time to clinical progression
  • To estimate progression-free survival (PFS) in each study arm

EXPLORATORY OBJECTIVE

  • To assess peripheral and tumor-based biomarkers of response and resistance in both cohorts.
  • To define the treatment-induced effects on circulating immune cells in both cohorts.
  • To explore remodeling of circulating T cell repertoire in both cohorts.
  • To explore the concordance of Prostate-Specific Membrane Antigen (PSMA) - Positron Emission Tomography (PET) scanning with conventional imaging in oligometastatic prostate cancer patients in both cohorts.

Details
Condition Prostatic Neoplasms
Treatment prednisone, Pembrolizumab, Leuprolide Acetate, stereotactic body radiation therapy, abiraterone acetate, SD-101
Clinical Study IdentifierNCT03007732
SponsorLawrence Fong
Last Modified on10 October 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note